Drug Profile
Testosterone transdermal - Warner Chilcott/Watson
Alternative Names: Intrinsa; Intrinsa CHF; Livensa; Testosterone transdermal TheraDerm MTX; WC3048; WC3049Latest Information Update: 13 Nov 2021
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Developer Noven Pharmaceuticals; Procter & Gamble; Warner Chilcott; Watson Laboratories
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone congener stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Female sexual dysfunction
- Suspended Heart failure
- No development reported Hypogonadism
- Discontinued Cachexia; Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
- 05 Jul 2013 No development reported - Phase-II for Hypogonadism in USA (Transdermal)